Kiniksa Pharmaceuticals InternationalvsMerck & Company

KNSA and MRK stock compared: price, dividend, valuation and results, from SEC filings.

KNSA

Kiniksa Pharmaceuticals International, plc

$95.05

Value $7.1B

-0.06%
KNSA's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Kiniksa Pharmaceuticals International (KNSA) has a market value of $7.1B and Merck & Company (MRK) $341B. Over the last year, with dividends, KNSA moved +129.6% and MRK +52.7%. The P/E is 64.4 for KNSA and 138.9 for MRK. Dividend yield: KNSA none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KNSA$7.1B

    MRK$341B

    MRK is 48 times KNSA

  • Revenue, 12 months

    KNSA$946M

    MRK$67.4B

    MRK is 71 times KNSA

  • Net income, 12 months

    KNSA$110M

    MRK$2.5B

    MRK is 22 times KNSA

  • Operating margin

    KNSA13.8%

    MRK–

  • ROIC

    KNSA15.9%

    MRK3.9%

    12.0 points apart

  • P/E

    KNSA64.4

    MRK138.9

    MRK is 2.2 times KNSA

  • Dividend yield

    KNSA0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    KNSA+637.4%

    MRK+94.3%

    543.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KNSA+637.4%

MRK+94.3%

20040060080020222023202420252026
Returns by period
PeriodKNSAWith dividendsMRKWith dividends
1 year since November 17, 2025+129.6%Price +129.6%+52.7%Price +48.4%
3 years since November 17, 2023+505.0%+82.2% a yearPrice +505.0%+48.4%+14.1% a yearPrice +35.4%
5 years since November 17, 2021+637.4%+49.1% a yearPrice +637.4%+94.3%+14.2% a yearPrice +66.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KNSAKiniksa Pharmaceuticals InternationalMRKMerck & Company

Valuation

KNSAMRK
Valuation
Price$95.05$137.78
Market value$7.1B$341B
Enterprise value (EV)$6.5B$385B
P/E64.4138.9
P/E, 5-year median55.014.8
P/B9.97.6
EV/EBIT49.780.8
Free cash flow yield2.8%4.3%

Results and growth

KNSAMRK
Results and growth
Revenue, 12 months$946M$67.4B
Net income, 12 months$110M$2.5B
Free cash flow, 12 months$197M$14.7B
Earnings per share, 12 months$1.31$0.98
Revenue growth, year on year60.1%1.3%
Revenue growth a year, past+104.8%over 4 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

KNSAMRK
Margins and returns on capital
Gross margin90.2%71.8%
Operating margin13.8%–
Net margin11.6%3.6%
ROIC15.9%3.9%
ROE17.8%5.2%

Balance sheet

KNSAMRK
Balance sheet
Cash$569M$9.7B
Total debt$7.9M$53.8B
Net debt / EBITDA-4.35.7
Interest cover–2.4×

Dividends and buybacks

KNSAMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KNSA or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Kiniksa Pharmaceuticals International or Merck & Company?

By market value, Merck & Company ($341B) is about 48.3 times Kiniksa Pharmaceuticals International ($7.1B), at today's prices.

How did KNSA and MRK stock do over the last 5 years?

Since November 17, 2021, KNSA's price moved +637.4% and MRK's +66.8%. With dividends: KNSA +637.4% (+49.1% a year), MRK +94.3% (+14.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, KNSA or MRK?

The dividend yield at today's price is none for Kiniksa Pharmaceuticals International and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of KNSA and MRK?

At today's price, the P/E is 64.4 for KNSA and 138.9 for MRK. The median of the last five years was 55.0 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Kiniksa Pharmaceuticals International or Merck & Company?

Over the last twelve months, the net margin was 11.6% for Kiniksa Pharmaceuticals International and 3.6% for Merck & Company, and the operating margin 13.8% and –. Revenue was $946M and $67.4B.

Which is the better investment, Kiniksa Pharmaceuticals International or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.